Weekly single-agent carboplatin in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma

European Journal of Gynaecological Oncology

Volumn 26, Issue 4, 2005, Pages 386-390

  Piura, B ^a   Meirovitz, M ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Carboplatin; Chemotherapy; Disease response; Ovarian carcinoma; Toxicity

Indexed keywords

CARBOPLATIN; GLUCOSE; PLATINUM;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TOLERABILITY; FEMALE; HUMAN; ISRAEL; LEUKOPENIA; NEUTROPENIA; OVARY CARCINOMA; PERITONEUM CANCER; THROMBOCYTOPENIA; UTERINE TUBE CARCINOMA;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARBOPLATIN; DRUG ADMINISTRATION SCHEDULE; FALLOPIAN TUBE NEOPLASMS; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 23744488941     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. McGuire W.P., Ozols R.F.: "Chemotherapy of advanced ovarian cancer". Semin. Oncol., 1998, 25, 340.
2. Spriggs D.: "Optimal sequencing in the treatment of recurrent ovarian cancer". Gynecol. Oncol., 2003, 90, S39.
3. Gonzalez-Martin A.: "Is combination chemotherapy superior to single-agent chemotherapy in second-line treatment?". Int. J. Gynecol. Cancer, 2003, 13 (suppl. 2), 185.
4. Bolis G., Scarfone G., Giardina G., Villa A., Mangili G., Melpignano M. et al.: "Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer". Gynecol. Oncol., 2001, 81, 3.
5. The International Collaborative Ovarian Neoplasm (ICON) Group, ICON 2: "Randomized trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer". Lancet, 1998, 352, 1571.
6. The International Collaborative Ovarian Neoplasm (ICON) Group.: "Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cispaltin in women with ovarian cancer: the ICON 3 randomized trial". Lancet, 2002, 360, 505.
7. Gore M.: "Carboplatin equals cisplatin: but how do I prescribe it?". J. Clin. Oncol., 2003, 21, 3183.
8. Gonzalez-Martin A.A., Calvo E., Bover I., Rubio M.J., Arcusa A., Casado A. et al.: "Randomized phase II study of carboplatin (C) versus paclitaxel-carboplatin (PC) in platinum-sensitive (PS) recurrent advanced ovarian carcinoma (AOC) with assessment of quality of life (QoL): A GEICO (Spanish Group for Investigation on Ovarian Carcinoma) study". 2003 American Society of Clinical Oncology (ASCO) Annual Meeting. Proc. Am. Soc. Clin. Oncol., 2003, 22, 451 (Abstract 1812).
9. Van der Burg M.E., Vergot I., Burger C.W., Van der Gaast A.: "Phase II study of weekly paclitaxel carboplatin in the treatment of progressive ovarian cancer". 2004 American Society of Clinical Oncology (ASCO) Annual Meeting. J. Clin. Oncol., 2004, 22, 14S (Abstract 5058).
10. Dunton CJ.: "Phase II study of weekly paclitaxel and weekly carboplatinum in recurrent platinum sensitive ovarian cancer". Proc. Am. Soc. Clin. Oncol., 2003, 22, 467 (Abstract 1876).
11. Havrilesky L.J., Alvarez A.A., Sayer R.A., Lancaster J.M., Soper J.T., Berchuck A. et al.: "Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer". Gynecol. Oncol., 2003, 88, 51.
12. Kikuchi A., Sakamoto H., Yamamoto T.: "Weekly carboplatin and paclitaxel is safe, active, and well tolerated in recurrent ovarian cancer cases of Japanese women previously treated with cisplatin-containing multidrug chemotherapy". Int. J. Gynecol. Cancer, 2005, 15, 45.
13. Calvert A.H., Newell D.R., Gumbrell L.A., O'Reilly S., Burnell M., Boxall F.E. et al.: "Carboplatin dosage: prospective evaluation of a simple formula based on renal function". J. Clin. Oncol., 1989, 7, 1748.
14. Calvert A.H., Egorin M.J.: "Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies". Eur. J. Cancer, 2002, 38, 11.
15. Common Terminology Criteria for Adverse Events, Version 3.0, Revised June 10, 2003, National Cancer Institute, http://ctep.cancer.gov/forms/CTCAEv3.pdf